EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

IL-2Rα is a Potential Biomarker for Heart Failure Diagnosis of Patients with End-Stage Renal Disease and Haemodialysis

Bingya Lv, Zhe Wang, Ya Suo, Shuai Shao, Meng Yuan, Yue Zhang, Lihua Wang, Guangping Li, Qiankun Bao iD

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Bingya Lv und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospi…. Hauptthemen laut MEDLINE: Heart Failure, Kidney Failure, Chronic, Renal Dialysis, Interleukin-2 Receptor alpha Subunit. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Scientific Research Program of Tianjin Municipal Education Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Heart failure (HF) is a leading cause of mortality in patients with end-stage renal disease (ESRD) undergoing haemodialysis. Identifying novel predictors of HF is essential for improving diagnostic precision and enhancing patient outcomes.

Methods

This study included 68 participants from the Haemodialysis Centre at the Second Hospital of Tianjin Medical University. Clinical characteristics and echocardiographic data were collected and analysed. We measured the plasma of 44 cytokines to investigate their correlation with cardiac function and their potential as HF biomarkers.

Results

In the HF with reduced ejection fraction (HFrEF) group, the levels of several cytokines, including stem cell growth factor-β (SCGF-β), C–X–C motif chemokine 10 (CXCL10), interleukin-1α (IL-1α), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-16 (IL-16), interleukin-1 receptor antagonist protein (IL-1Ra), interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α), leukaemia inhibitory factor (LIF), C–C motif chemokine 3 (CCL3), interleukin-10 (IL-10), interleukin-2 receptor subunit alpha (IL-2Rα), tumour necrosis factor ligand superfamily member 10 (TNFSF10), macrophage colony-stimulating factor (M-CSF), granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF), were significantly increased, while C–C motif chemokine 11 (CCL11)/eotaxin levels were decreased compared with those in the control group (P < 0.05). Receiver operating characteristic (ROC) curve analysis highlighted TNF-α [area under the ROC curve (AUC) = 0.85, odds ratio (OR) = 1.080, 95% confidence interval (CI): 1.033–1.128, P = 0.001], IFN-γ (AUC = 0.84, OR = 1.836, 95% CI: 1.289–2.615, P = 0.003) and IL-2Rα (AUC = 0.82, OR = 1.022, 95% CI: 1.009–1.035, P = 0.001) as excellent predictors for HFrEF in haemodialysis patients with ESRD, and they outperformed soluble suppression of tumourigenicity-2 (sST2) but slightly underperformed N-terminal pro-brain natriuretic peptide (NT-proBNP). IL-2Rα (AUC = 0.77, OR = 1.018, 95% CI: 1.007–1.030, P = 0.001) demonstrated superior diagnostic capabilities when distinguishing patients with HF with left ventricular ejection fraction (LVEF) <50% from controls. IL-2Rα emerged as a robust biomarker for left ventricular HF, while TNF-α (AUC = 0.89, OR = 1.140, 95% CI: 1.039–1.250, P = 0.005) showed promise in assessing HF severity in patients with ESRD. IL-2Rα (AUC = 0.80, OR = 1.017, 95% CI: 1.007–1.027, P = 0.001) also significantly predicted right ventricular systolic dysfunction. During a median follow-up of 14 months, 10 patients (14.7%) experienced all-cause mortality. Multivariate Cox regression analysis confirmed that plasma IL-2Rα was an independent predictor of all-cause death [hazard ratio (HR): 1.010, 95% CI: 1.001–1.020, P = 0.039] after adjusting for other variables.

Conclusions

This study underscores the potential of IL-2Rα as a valuable biomarker for HF diagnosis and management in haemodialysis patients with ESRD and contributes to our understanding of this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureKidney Failure, ChronicRenal DialysisInterleukin-2 Receptor alpha SubunitStroke VolumeHumansMaleFemaleBiomarkersMiddle AgedAgedEchocardiographyROC CurvePrognosisFollow-Up Studies

Stichwörter der Autor:innen

IL‐2Rαcytokineend‐stage renal diseaseheart failureinflammation

Substanzen

BiomarkersInterleukin-2 Receptor alpha Subunit

Autor:innen und Institutionen

  • Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
  • Department of Kidney Disease and Blood Purification Centre, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.

ORCID-Profile: Qiankun Bao

Förderung

  • Scientific Research Program of Tianjin Municipal Education Commission

Zitieren

APA

Lv, B., Wang, Z., Suo, Y., Shao, S., Yuan, M., Zhang, Y., Wang, L., Li, G., & Bao, Q. (2025). IL-2Rα is a Potential Biomarker for Heart Failure Diagnosis of Patients with End-Stage Renal Disease and Haemodialysis. ESC Heart Failure. https://doi.org/10.1002/ehf2.15051

Vancouver

Lv B, Wang Z, Suo Y, Shao S, Yuan M, Zhang Y, et al. IL-2Rα is a Potential Biomarker for Heart Failure Diagnosis of Patients with End-Stage Renal Disease and Haemodialysis. ESC Heart Failure. 2025. doi:10.1002/ehf2.15051

BibTeX
@article{Lv2025,
  author = {Lv, Bingya and Wang, Zhe and Suo, Ya and Shao, Shuai and Yuan, Meng and Zhang, Yue and Wang, Lihua and Li, Guangping and Bao, Qiankun},
  title = {IL-2Rα is a Potential Biomarker for Heart Failure Diagnosis of Patients with End-Stage Renal Disease and Haemodialysis},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15051}
}
Kostenlos starten →